# Taysha Gene Therapies (TSHA) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TSHA
## Company Profile
- Ticker: TSHA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, CNS
## Stock Data
- Close: 6.405 USD
- Market cap: 1635084203.8000002 USD
- Last updated: 2026-08-12
## Business Overview
### CNS Gene Therapy Focus
Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease.
### Lead Rett Syndrome Program
TSHA-102 is an intrathecally delivered AAV9 gene therapy for Rett syndrome. It delivers a functional form of MECP2 and incorporates Taysha's miRARE auto-regulatory technology, which is designed to control MECP2 expression on a cell-by-cell basis.
### Pivotal Development Strategy
TSHA-102 is being evaluated in the REVEAL pivotal trial and the ASPIRE study. Following discussions with the FDA, Taysha may be able to support a biologics license application using the six-month interim analysis from REVEAL.
### Regulatory and Manufacturing Readiness
TSHA-102 has received multiple expedited and orphan designations in the United States, Europe, and the United Kingdom. Taysha is also conducting process-performance qualification work to establish BLA-enabling manufacturing readiness.
## Why The Stock Is Moving

Following the latest company update, “Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update”, TSHA closed down 4.12% at $6.41 on Aug 12, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Completion of the BLA-enabling process-performance qualification campaign for TSHA-102 in the fourth quarter of 2026.
- Topline data from the six-month interim analysis of the REVEAL pivotal trial and FDA feedback on the TSHA-102 BLA pathway in the first half of 2027.

## Drug Assets

- TSHA-102

## Recent News
- 2026-08-11 20:00 EST — [Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-reports-second-quarter-2026-financial-results-and-provides-5e47b159) — Source: Taysha Gene Therapies
- 2026-08-07 12:00 EST — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--1abe04ba) — Source: Taysha Gene Therapies
- 2026-08-04 20:00 EST — [Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-to-release-second-quarter-2026-financial-results-and-host--45ec0663) — Source: Taysha Gene Therapies
- 2026-08-03 12:00 EST — [Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-and-catalent-expand-strategic-partnership-to-include-futur-b3e4fc14) — Source: Taysha Gene Therapies
- 2026-06-25 20:01 EST — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies